These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. Evans DA; Harmer D; Downham DY; Whibley EJ; Idle JR; Ritchie J; Smith RL J Med Genet; 1983 Oct; 20(5):321-9. PubMed ID: 6644761 [TBL] [Abstract][Full Text] [Related]
27. Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation. Philip PA; Lewis LD; James CA; Rogers HJ Cancer Chemother Pharmacol; 1988; 22(4):321-4. PubMed ID: 3168145 [TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetics and drug metabolism: an Irish perspective. Holland P; Barry M; Feely J Ir J Med Sci; 1991 Feb; 160(2):54-6. PubMed ID: 1917424 [TBL] [Abstract][Full Text] [Related]
29. A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians. Mahgoub A; Idle JR; Smith RL Xenobiotica; 1979 Jan; 9(1):51-6. PubMed ID: 760321 [TBL] [Abstract][Full Text] [Related]
30. Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype. Veronese ME; McLean S Eur J Clin Pharmacol; 1991; 40(6):547-52. PubMed ID: 1884734 [TBL] [Abstract][Full Text] [Related]
31. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin. Lennard MS; McGourty JC; Silas JH Br J Clin Pharmacol; 1988 Feb; 25(2):276-8. PubMed ID: 3358891 [TBL] [Abstract][Full Text] [Related]
32. Lack of congruence of S-carboxymethyl-L-cysteine sulphoxidation and debrisoquine 4-hydroxylation in a Caucasian population. Haley CS; Waring RH; Mitchell SC; Shah RR; Idle JR; Smith RL Xenobiotica; 1985 May; 15(5):445-50. PubMed ID: 4036168 [TBL] [Abstract][Full Text] [Related]
33. Diurnal effects on debrisoquine hydroxylation phenotyping. Lee EJ Eur J Clin Pharmacol; 1988; 35(4):441-2. PubMed ID: 3197754 [TBL] [Abstract][Full Text] [Related]
34. Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Sommers DK; Moncrieff J; Avenant J Hum Toxicol; 1989 Sep; 8(5):365-8. PubMed ID: 2807305 [TBL] [Abstract][Full Text] [Related]
35. N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome. Siegmund W; Fengler JD; Franke G; Zschiesche M; Eike O; Eike E; Meisel P; Wulkow R Br J Clin Pharmacol; 1991 Oct; 32(4):467-72. PubMed ID: 1958441 [TBL] [Abstract][Full Text] [Related]
36. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Graf T; Broly F; Hoffmann F; Probst M; Meyer UA; Howald H Eur J Clin Pharmacol; 1992; 43(4):399-403. PubMed ID: 1451720 [TBL] [Abstract][Full Text] [Related]
37. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565 [TBL] [Abstract][Full Text] [Related]
38. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021 [TBL] [Abstract][Full Text] [Related]
39. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Brøsen K; Gram LF; Haghfelt T; Bertilsson L Pharmacol Toxicol; 1987 Apr; 60(4):312-4. PubMed ID: 3588528 [TBL] [Abstract][Full Text] [Related]
40. The metabolism of debrisoquine in man: (1) regioselectivity of hydroxylation and (2) aberrant oxidative metabolism in two sibling patients with carbimazole-induced agranulocytosis. Ritchie JC; Crothers MJ; Shah RR; Idle JR; Smith RL Xenobiotica; 1986 May; 16(5):503-9. PubMed ID: 3739370 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]